Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 24, 2017

DrugPatentWatch Database Preview

Insulin recombinant human - Generic Drug Details

« Back to Dashboard

What are the generic sources for insulin recombinant human and what is the scope of insulin recombinant human freedom to operate?

Insulin recombinant human
is the generic ingredient in eleven branded drugs marketed by Novo Nordisk Inc, Lilly, Pfizer, and Mannkind, and is included in nine NDAs. There are thirty-nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Insulin recombinant human has seven hundred and six patent family members in sixty-one countries.

There are thirty-eight drug master file entries for insulin recombinant human. Seven suppliers are listed for this compound.

Summary for Generic Name: insulin recombinant human

Drug Master File Entries: see list38
Suppliers / Packagers: see list7
Clinical Trials: see list4,613
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:insulin recombinant human at DailyMed

Pharmacology for Ingredient: insulin recombinant human

Drug ClassInsulin
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
insulin recombinant human
POWDER;INHALATION022472-003Apr 17, 2015RXYesNo8,215,300► SubscribeY ► Subscribe
insulin recombinant human
POWDER;INHALATION022472-003Apr 17, 2015RXYesNo9,339,615► SubscribeY ► Subscribe
insulin recombinant human
POWDER;INHALATION022472-002Jun 27, 2014RXYesYes7,648,960► Subscribe ► Subscribe
insulin recombinant human
POWDER;INHALATION022472-001Jun 27, 2014RXYesNo7,943,572► Subscribe ► Subscribe
insulin recombinant human
POWDER;INHALATION022472-001Jun 27, 2014RXYesNo9,192,675► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Formulary management
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus